New Test for assessing Prostrate Cancer metastasis risk

New Test for assessing Prostrate Cancer metastasis risk

Headlines Health

The growing tendency of metastatic state without any warning has led to researchers seeking better investigation methods to avoid the danger. In 2015 within United States there were 3,120,176 men that had tested positive for prostate cancer and recent data from National Cancer Institute shows that around 11.2 % men in the country are likely to have diagnosis of prostate cancer in their lifetime. As the risk of the disease turning from mild to aggressive within months is quite common doctors now advice patients to undergo a new type of test to check risk of metastasis.

This new test for accessing metastasis condition of prostate cancer has been developed by researchers from Albert Einstein College of Medicine in NYC which is both cheap and fast when compared to existing testing methods and uses just a few tissue samples of a patient. The new test will detect copy number alterations or CAN’s that are actually changes in the patient’s genome which leads to spread of cancer causing tumors. When specialists are able to access the existence of CNA’s in blood and tissue samples they can gauge if the cancer cells are proliferating or not.

According to the study’s lead author, Dr. Harry Ostrer, it has been demonstrated that with the new technology of Next Generation Copy Number Alteration Assay it is easier to detect presence and movement of CNA’s. This will help doctors to advice aggressive treatment and surveillance methods for patients that have metastasis prone illness and leave those that have indolent form of prostate cancer. Details of the study and research were presented in Journal of Molecular Diagnostics in which it claims that this NG-CNA test can analyze samples from 902 genomic sites and in 194 genomic regions and provide results faster and at lesser cost than existing tests for prostate cancer.